期刊
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
卷 96, 期 2, 页码 220-256出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2015.05.012
关键词
Ovarian cancer; ABC transporter; Chemoresistance; Multi-drug resistance; Prognosis; Clinical trials
资金
- Ovarian Cancer Research Foundation (OCRF), Australia
- Royal Adelaide Hospital Clinical Research Fund
- Cancer Council of South Australia
- South Australian Health and Medical Research Institute
Over 80% of ovarian cancer patients develop chemoresistance which results in a lethal course of the disease. A well-established cause of chemoresistance involves the family of ATP-binding cassette transporters, or ABC transporters that transport a wide range of substrates including metabolic products, nutrients, lipids, and drugs across extra- and intra-cellular membranes. Expressions of various ABC transporters, shown to reduce the intracellular accumulation of chemotherapy drugs, are increased following chemotherapy and impact on ovarian cancer survival. Although clinical trials to date using ABC transporter inhibitors have been disappointing, ABC transporter inhibition remains an attractive potential adjuvant to chemotherapy. A greater understanding of their physiological functions and role in ovarian cancer chemoresistance will be important for the development of more effective targeted therapies. This article will review the role of the ABC transporter family in ovarian cancer progression and chemoresistance as well as the clinical attempts used to date to reverse chemoresistance. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据